NO20090235L - Kondenserte sykliske forbindelser - Google Patents

Kondenserte sykliske forbindelser

Info

Publication number
NO20090235L
NO20090235L NO20090235A NO20090235A NO20090235L NO 20090235 L NO20090235 L NO 20090235L NO 20090235 A NO20090235 A NO 20090235A NO 20090235 A NO20090235 A NO 20090235A NO 20090235 L NO20090235 L NO 20090235L
Authority
NO
Norway
Prior art keywords
cyclic compounds
condensed cyclic
compound
salt
prodrug
Prior art date
Application number
NO20090235A
Other languages
English (en)
Norwegian (no)
Inventor
Tsuneo Yasuma
Nobuyuki Negoro
Masayuki Mashita
Masahiro Itou
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of NO20090235L publication Critical patent/NO20090235L/no

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/77—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D307/78—Benzo [b] furans; Hydrogenated benzo [b] furans
    • C07D307/79—Benzo [b] furans; Hydrogenated benzo [b] furans with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the hetero ring
    • C07D307/80—Radicals substituted by oxygen atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Obesity (AREA)
  • Immunology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Psychiatry (AREA)
  • Urology & Nephrology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Reproductive Health (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Oncology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Nutrition Science (AREA)
  • Dermatology (AREA)
  • Vascular Medicine (AREA)
NO20090235A 2006-06-27 2009-01-14 Kondenserte sykliske forbindelser NO20090235L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2006177099 2006-06-27
PCT/JP2007/063208 WO2008001931A2 (en) 2006-06-27 2007-06-26 Fused cyclic compounds

Publications (1)

Publication Number Publication Date
NO20090235L true NO20090235L (no) 2009-02-16

Family

ID=38656568

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20090235A NO20090235L (no) 2006-06-27 2009-01-14 Kondenserte sykliske forbindelser

Country Status (36)

Country Link
US (5) US7732626B2 (sr)
EP (4) EP2248812B1 (sr)
JP (3) JP4401428B2 (sr)
KR (1) KR101058772B1 (sr)
CN (4) CN103083307A (sr)
AR (1) AR061644A1 (sr)
AT (1) ATE543815T1 (sr)
AU (1) AU2007265966B2 (sr)
BR (1) BRPI0713378A8 (sr)
CA (2) CA2838448A1 (sr)
CL (1) CL2007001873A1 (sr)
CO (1) CO6160234A2 (sr)
CR (1) CR10564A (sr)
CY (2) CY1112705T1 (sr)
DK (2) DK2041123T3 (sr)
ES (2) ES2450081T3 (sr)
GE (1) GEP20115359B (sr)
HR (2) HRP20120333T1 (sr)
IL (1) IL195947A (sr)
JO (1) JO2969B1 (sr)
MA (1) MA30537B1 (sr)
ME (1) ME00535B (sr)
MX (1) MX2008016274A (sr)
MY (1) MY154798A (sr)
NO (1) NO20090235L (sr)
NZ (1) NZ574038A (sr)
PE (1) PE20080993A1 (sr)
PL (2) PL2041123T3 (sr)
PT (2) PT2041123E (sr)
RS (2) RS52307B (sr)
RU (1) RU2444521C2 (sr)
SI (2) SI2041123T1 (sr)
TW (1) TWI354668B (sr)
UA (1) UA95296C2 (sr)
WO (1) WO2008001931A2 (sr)
ZA (1) ZA200900154B (sr)

Families Citing this family (150)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
CN102083783A (zh) 2007-10-10 2011-06-01 安姆根有限公司 取代的联苯gpr40调节剂
WO2009111056A1 (en) * 2008-03-06 2009-09-11 Amgen Inc. Conformationally constrained carboxylic acid derivatives useful for treating metabolic disorders
WO2009117421A2 (en) * 2008-03-17 2009-09-24 Kalypsys, Inc. Heterocyclic modulators of gpr119 for treatment of disease
US8586607B2 (en) 2008-07-28 2013-11-19 Syddansk Universitet Compounds for the treatment of metabolic diseases
TW201014850A (en) 2008-09-25 2010-04-16 Takeda Pharmaceutical Solid pharmaceutical composition
AU2009303475B2 (en) 2008-10-15 2012-09-13 Amgen Inc. Spirocyclic GPR40 modulators
JP5535931B2 (ja) 2008-10-27 2014-07-02 武田薬品工業株式会社 二環性化合物
AR074760A1 (es) * 2008-12-18 2011-02-09 Metabolex Inc Agonistas del receptor gpr120 y usos de los mismos en medicamentos para el tratamiento de diabetes y el sindrome metabolico.
EP2371826A4 (en) 2008-12-29 2012-06-27 Takeda Pharmaceutical NEW CONNECTION WITH CONDENSED RINGS AND ITS USE
AR075158A1 (es) 2009-01-27 2011-03-16 Takeda Pharmaceutical Derivados de pirrolopirimidinas, composiciones farmaceuticas y usos.
EP2423176A4 (en) 2009-04-22 2012-11-07 Astellas Pharma Inc CARBOXYLIC ACID COMPOUND
WO2010143733A1 (en) 2009-06-09 2010-12-16 Takeda Pharmaceutical Company Limited Novel fused cyclic compound and use thereof
EP2460523B1 (en) 2009-07-28 2017-01-04 Takeda Pharmaceutical Company Limited Tablet
JPWO2011052756A1 (ja) 2009-10-30 2013-03-21 持田製薬株式会社 新規３−ヒドロキシ−５−アリールイソキサゾール誘導体
NZ601408A (en) 2009-12-25 2013-12-20 Mochida Pharm Co Ltd Novel 3-hydroxy-5-arylisothiazole derivative
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
AR080969A1 (es) 2010-04-27 2012-05-23 Takeda Pharmaceutical Compuesto biciclico
TWI511967B (zh) 2010-06-16 2015-12-11 Takeda Pharmaceutical 醯胺化合物之結晶
US8299117B2 (en) 2010-06-16 2012-10-30 Metabolex Inc. GPR120 receptor agonists and uses thereof
WO2011157827A1 (de) 2010-06-18 2011-12-22 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
US20130184272A1 (en) 2010-09-17 2013-07-18 Takeda Pharmaceutical Company Limited Diabetes therapeutic agent
JP5809157B2 (ja) 2010-10-08 2015-11-10 持田製薬株式会社 環状アミド誘導体
KR20140001965A (ko) 2010-11-30 2014-01-07 다케다 야쿠힌 고교 가부시키가이샤 바이시클릭 화합물
AR084050A1 (es) 2010-12-01 2013-04-17 Boehringer Ingelheim Int Acidos indaniloxidihidrobenzofuranilaceticos
WO2012111849A1 (en) 2011-02-17 2012-08-23 Takeda Pharmaceutical Company Limited Production method of optically active dihydrobenzofuran derivative
HK1207853A1 (en) 2011-04-08 2016-02-12 卡尔丹治疗有限公司 Ortho-fluoro substituted compounds for the treatment of metabolic diseases
BR112013027883A2 (pt) 2011-04-27 2017-08-08 Mochida Pharm Co Ltd novo derivado de 1-óxido de 3-hidroxiisotiazol
AU2012248627A1 (en) 2011-04-28 2013-11-14 Mochida Pharmaceutical Co., Ltd. Cyclic amide derivative
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
CN103012343B (zh) * 2011-09-26 2015-04-08 上海恒瑞医药有限公司 稠合环类衍生物、其制备方法及其在医药上的应用
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JPWO2013061962A1 (ja) 2011-10-24 2015-04-02 武田薬品工業株式会社 二環性化合物
CN103429581B (zh) * 2012-01-12 2015-08-26 江苏恒瑞医药股份有限公司 多环类衍生物、其制备方法及其在医药上的应用
EP2802571A1 (en) 2012-01-12 2014-11-19 Takeda Pharmaceutical Company Limited Benzimidazole derivatives as mch receptor antagonists
GB2498968A (en) * 2012-02-01 2013-08-07 Prosidion Ltd Pharmaceutical combination of a GPR119 agonist and a GPR40 agonist
US9382188B2 (en) 2012-02-13 2016-07-05 Takeda Pharmaceutical Company Limited Aromatic ring compound
US9181186B2 (en) 2012-02-13 2015-11-10 Takeda Pharmaceutical Company Limited Aromatic ring compound
WO2013122260A1 (en) 2012-02-15 2013-08-22 Takeda Pharmaceutical Company Limited Tablet
JP6106179B2 (ja) * 2012-02-24 2017-03-29 武田薬品工業株式会社 芳香環化合物
NZ631569A (en) 2012-02-28 2016-10-28 Piramal Entpr Ltd Phenyl alkanoic acid derivatives as gpr agonists
US8642585B2 (en) * 2012-03-26 2014-02-04 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
CN104350040B (zh) 2012-03-29 2016-06-01 武田药品工业株式会社 芳环化合物
US8809376B2 (en) * 2012-04-30 2014-08-19 Boehringer Ingelheim International Gmbh Indanyloxydihydrobenzofuranylacetic acids
EP2848621A4 (en) 2012-05-10 2016-06-01 Takeda Pharmaceutical AROMATIC RING CONNECTION
US9505772B2 (en) 2012-05-10 2016-11-29 Takeda Pharmaceutical Company Limited Aromatic ring compound
AR092843A1 (es) 2012-06-05 2015-05-06 Takeda Pharmaceuticals Co Preparacion solida
CA2878625A1 (en) 2012-07-11 2014-01-16 Elcelyx Therapeutics, Inc. Compositions comprising statins, biguanides and further agents for reducing cardiometabolic risk
JP2015127299A (ja) 2012-07-19 2015-07-09 武田薬品工業株式会社 固形製剤
US9527875B2 (en) 2012-08-02 2016-12-27 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
RS61242B1 (sr) 2012-09-04 2021-01-29 Shanghai hengrui pharmaceutical co ltd Derivati imidazolina, postupci njihove pripreme i njihove primene u medicini
WO2014064215A1 (en) 2012-10-24 2014-05-01 INSERM (Institut National de la Santé et de la Recherche Médicale) TPL2 KINASE INHIBITORS FOR PREVENTING OR TREATING DIABETES AND FOR PROMOTING β-CELL SURVIVAL
TWI692469B (zh) * 2012-11-09 2020-05-01 南韓商Ｌｇ化學股份有限公司 Ｇｐｒ４０受體促效劑，製造該促效劑的方法以及含有該促效劑作爲活性劑的醫藥組成物
WO2014078610A1 (en) 2012-11-16 2014-05-22 Bristol-Myers Squibb Company Dihydropyrazole gpr40 modulators
PE20150968A1 (es) 2012-11-28 2015-07-09 Boehringer Ingelheim Int Nuevos acidos indaniloxi dihidrobenzofuranil aceticos
JP6283862B2 (ja) 2012-12-07 2018-02-28 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規インダニルオキシジヒドロベンゾフラニル酢酸
EP2953681B1 (en) 2013-02-06 2017-03-15 Boehringer Ingelheim International GmbH New indanyloxydihydrobenzofuranylacetic acids
RU2015140066A (ru) 2013-02-22 2017-03-30 Мерк Шарп И Доум Корп. Противодиабетические бициклические соединения
EP2963027B1 (en) * 2013-02-28 2018-12-26 TiumBio Co., Ltd. Tricyclic compound and use thereof
CN103145663B (zh) * 2013-03-01 2016-03-23 上海高准医药有限公司 (s)-2-(2,3-二氢苯并呋喃-3-基)乙酸衍生物，其制备方法及其在医药上的应用
WO2014142363A1 (en) 2013-03-14 2014-09-18 Takeda Pharmaceutical Company Limited Spiro azetidine isoxazole derivatives and their use as sstr5 antagonists
CN104059039B (zh) * 2013-03-22 2017-03-15 正大天晴药业集团股份有限公司 具有gpr40受体功能调节作用的稠环化合物
US10005720B2 (en) 2013-04-05 2018-06-26 North Carolina Central University Compounds useful for the treatment of metabolic disorders and synthesis of the same
AR096041A1 (es) 2013-04-17 2015-12-02 Piramal Entpr Ltd Derivados de ácido carboxílico alquilo sustituidos como agonistas rpg
WO2014187343A1 (zh) * 2013-05-22 2014-11-27 四川海思科制药有限公司 苯并呋喃衍生物、其制备方法及其在医药上的应用
CN104250238B (zh) * 2013-06-25 2017-12-26 南京圣和药业股份有限公司 Gpr40激动剂及其应用
CN104250239B (zh) * 2013-06-29 2016-09-07 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
WO2015000412A1 (zh) * 2013-07-02 2015-01-08 四川海思科制药有限公司 苯并环丁烯类衍生物、其制备方法及其在医药上的应用
EP3019487A1 (en) 2013-07-09 2016-05-18 Takeda Pharmaceutical Company Limited Heterocyclic compound
PT3031799T (pt) 2013-08-09 2018-07-04 Takeda Pharmaceuticals Co Composto aromático
CN104370864B (zh) * 2013-08-14 2016-04-13 成都苑东生物制药股份有限公司 一种2-(6-羟基-2,3-二氢苯并呋喃-3-基)乙腈化合物和以该化合物制备tak-875药物的方法
WO2015032328A1 (zh) * 2013-09-03 2015-03-12 四川海思科制药有限公司 茚满衍生物及其制备方法和在医药上的应用
JO3442B1 (ar) 2013-10-07 2019-10-20 Takeda Pharmaceuticals Co مضادات ذات نوع فرعي من مستقبل سوماتوستاتين 5 (sstr5)
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2015062486A1 (en) * 2013-10-31 2015-05-07 Sunshine Lake Pharma Co., Ltd. Biphenyl compounds and uses thereof
IN2013MU03577A (sr) 2013-11-14 2015-07-31 Cadila Healthcare Ltd
ES2747973T3 (es) 2013-11-15 2020-03-12 Merck Sharp & Dohme Compuestos tricíclicos antidiabéticos
CN104650055A (zh) * 2013-11-22 2015-05-27 山东轩竹医药科技有限公司 芳香多环羧酸衍生物
EP3076959B1 (en) 2013-12-04 2018-07-04 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2015089809A1 (en) 2013-12-19 2015-06-25 Merck Sharp & Dohme Corp. Antidiabetic substituted heteroaryl compounds
EP3102198B1 (en) 2014-02-06 2020-08-26 Merck Sharp & Dohme Corp. Antidiabetic compounds
US9346776B2 (en) 2014-02-13 2016-05-24 Takeda Pharmaceutical Company Limited Fused heterocyclic compound
US9428470B2 (en) 2014-02-13 2016-08-30 Takeda Pharmaceutical Company Limited Heterocyclic compound
CN105001212B (zh) * 2014-04-16 2018-01-16 江苏柯菲平医药股份有限公司 稠环化合物及其制备方法和应用
WO2015176267A1 (en) 2014-05-22 2015-11-26 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
US10662171B2 (en) 2014-08-08 2020-05-26 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US10968193B2 (en) 2014-08-08 2021-04-06 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2016022446A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [5,6]-fused bicyclic antidiabetic compounds
WO2016019587A1 (en) 2014-08-08 2016-02-11 Merck Sharp & Dohme Corp. [7, 6]-fused bicyclic antidiabetic compounds
CN104177320B (zh) * 2014-08-27 2016-03-02 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
CN104193731B (zh) * 2014-08-27 2017-03-15 广东东阳光药业有限公司 一种脲取代联苯类化合物及其组合物及用途
WO2016060517A2 (ko) * 2014-10-17 2016-04-21 현대약품 주식회사 신규한 3-(4- (벤질옥시)페닐)핵스- 4-이노익 산 유도체 및 다른 유효 성분을 포함하는 대사성 질환의 예방 또는 치료용 복합제제
US10426818B2 (en) 2015-03-24 2019-10-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Method and pharmaceutical composition for use in the treatment of diabetes
CN105418563B (zh) * 2015-12-28 2017-11-10 山东大学 Tak‑875类似物及其制备方法与应用
WO2017172505A1 (en) 2016-03-29 2017-10-05 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
WO2018118670A1 (en) 2016-12-20 2018-06-28 Merck Sharp & Dohme Corp. Antidiabetic spirochroman compounds
JP7050792B2 (ja) 2017-01-26 2022-04-08 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング ベンジルオキシピラジニルシクロプロパンカルボン酸、その医薬組成物及び使用
CN110177773B (zh) 2017-01-26 2023-08-25 勃林格殷格翰国际有限公司 苄基氨基吡啶基环丙烷羧酸、其药物组合物及其用途
EP3573959B1 (en) 2017-01-26 2021-07-28 Boehringer Ingelheim International GmbH Benzylaminopyrazinylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10913720B2 (en) 2017-01-26 2021-02-09 Boehringer Ingelheim International Gmbh Benzyloxypyridylcyclopropanecarboxylic acids, pharmaceutical compositions and uses thereof
US10550127B1 (en) 2017-02-08 2020-02-04 Boehringer Ingelheim International Gmbh Indanylaminoazadihydrobenzofuranylacetic acids, pharmaceutical compositions for the treatment of diabetes
AR111307A1 (es) 2017-03-30 2019-06-26 Takeda Pharmaceuticals Co Derivados de 1’,2’-dihidroespiro[ciclohexan-1,3’-indol] o 1’,2’-dihidroespiro[ciclohexan-1,3’-pirrolo[3,2-b]piridina] como inhibidores de hexakisfosfato quinasa
JPWO2018181847A1 (ja) 2017-03-31 2020-03-05 武田薬品工業株式会社 芳香環化合物
JOP20190211A1 (ar) 2017-03-31 2019-09-15 Takeda Pharmaceuticals Co ببتيد منشط لمستقبل gip
AR111199A1 (es) 2017-03-31 2019-06-12 Takeda Pharmaceuticals Co Compuesto aromático agonista de gpr40
BR102018007822A2 (pt) 2017-04-20 2018-11-06 Gilead Sciences, Inc. composto, métodos para inibir pd-1, pd-l1 e/ou interação de pd-1/pd-l1 e para tratamento de câncer, composição farmacêutica, e, kit para tratamento de ou prevenção de câncer ou uma doença ou condição
EP3709995A4 (en) 2017-11-16 2021-04-14 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
US11964938B2 (en) 2018-01-08 2024-04-23 Celon Pharma S.A. 3-phenyl-4-hexynoic acid derivatives as GPR40 agonists
TWI707849B (zh) 2018-02-13 2020-10-21 美商基利科學股份有限公司 Pd‐1/pd‐l1抑制劑
CN110294744A (zh) * 2018-03-21 2019-10-01 中国医学科学院药物研究所 Gpr40受体激动剂、其制法和其药物组合物与用途
WO2019183577A1 (en) 2018-03-23 2019-09-26 Carmot Therapeutics, Inc. Modulators of g-protein coupled receptors
KR102591947B1 (ko) 2018-04-19 2023-10-25 길리애드 사이언시즈, 인코포레이티드 Pd-1/pd-l1 억제제
EP3820572B1 (en) 2018-07-13 2023-08-16 Gilead Sciences, Inc. Pd-1/pd-l1 inhibitors
EP3650440A4 (en) 2018-08-27 2020-11-25 Scohia Pharma, Inc. BENZOIC ESTER COMPOUND
EP3856339A1 (en) 2018-09-24 2021-08-04 Takeda Pharmaceutical Company Limited Gip receptor agonist peptide compounds and uses thereof
JP2022503793A (ja) 2018-09-24 2022-01-12 武田薬品工業株式会社 Ｇｉｐ受容体アゴニストペプチド化合物及びその使用
US11236085B2 (en) 2018-10-24 2022-02-01 Gilead Sciences, Inc. PD-1/PD-L1 inhibitors
WO2020166662A1 (ja) * 2019-02-13 2020-08-20 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
US20220071925A1 (en) * 2019-02-13 2022-03-10 Gexval Inc. Medicinal composition for preventing or treating bone diseases
CN119841865A (zh) 2020-02-07 2025-04-18 加舒布鲁姆生物公司 杂环glp-1激动剂
AR121650A1 (es) 2020-03-25 2022-06-22 Takeda Pharmaceuticals Co Dosificación qd de compuestos peptídicos agonistas del receptor de gip y sus usos
EP4126920A2 (en) 2020-03-25 2023-02-08 Takeda Pharmaceutical Company Limited Gif receptor agonist peptide compounds and uses thereof
FI4143183T3 (fi) 2020-04-29 2026-01-07 Gasherbrum Bio Inc Heterosyklisiä glp-1-agonisteja
JP7748104B2 (ja) * 2020-08-12 2025-10-02 株式会社ジェクスヴァル 骨疾患の予防または治療用の医薬組成物
WO2022133111A1 (en) * 2020-12-16 2022-06-23 Regents Of The University Of Minnesota Cubanyl biguanide compounds
IL308392A (en) 2021-05-13 2024-01-01 Carmot Therapeutics Inc G protein-coupled receptor modulators
CN119137124A (zh) 2022-03-09 2024-12-13 加舒布鲁姆生物公司 杂环glp-1激动剂
WO2023179542A1 (en) 2022-03-21 2023-09-28 Gasherbrum Bio , Inc. 5,8-dihydro-1,7-naphthyridine derivatives as glp-1 agonists for the treatment of diabetes
WO2023198140A1 (en) 2022-04-14 2023-10-19 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
JP2026501171A (ja) 2022-12-15 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド Ｇｌｐ－１アゴニスト活性を有する化合物の塩および固体形態
JP2026501285A (ja) 2022-12-22 2026-01-14 ガシャーブラム・バイオ・インコーポレイテッド ヘテロ環式ｇｌｐ－１アゴニスト
CN120693338A (zh) 2022-12-22 2025-09-23 加舒布鲁姆生物公司 杂环的glp-1激动剂
AU2024222719A1 (en) 2023-02-16 2025-08-21 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
US20250019389A1 (en) 2023-06-30 2025-01-16 Gasherbrum Bio, Inc. Heterocyclic agonists
WO2025015269A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Compounds, compositions, and methods
WO2025015268A1 (en) 2023-07-13 2025-01-16 Aconcagua Bio, Inc. Modulators of calcitonin receptor and/or amylin receptor activity
WO2025045208A1 (en) 2023-08-31 2025-03-06 Gasherbrum Bio, Inc. Heteroaryl-heterocycloalkyl-based glp-1 agonists
WO2025137307A1 (en) 2023-12-20 2025-06-26 Gasherbrum Bio, Inc. Heterocyclic glp-1 agonists
CN117865851A (zh) * 2024-01-10 2024-04-12 上海吉奉生物科技有限公司 一种Fmoc-2,6-二甲基酪氨酸的合成方法
WO2025154020A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025154021A1 (en) 2024-01-19 2025-07-24 Takeda Pharmaceutical Company Limited Improved gip receptor agonist peptide compounds and uses thereof
WO2025171340A1 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. The treatment of calcitonin- and/or amylin-receptor associated conditions
WO2025171341A2 (en) 2024-02-08 2025-08-14 Aconcagua Bio, Inc. Compounds and compositions for treating conditions associated with calcitonin receptor and/or amylin receptor activity
WO2026041075A1 (en) 2024-08-21 2026-02-26 Gasherbrum Bio, Inc. Gpl-1 agonists
WO2026051998A1 (en) 2024-09-04 2026-03-12 Aconcagua Bio, Inc. Compounds, compositions, and methods

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9309324D0 (en) * 1993-05-06 1993-06-16 Bayer Ag Venzofuranyl-and-thiophenyl-alkanecarboxyclic acids derivatives
US5612330A (en) 1994-03-07 1997-03-18 Warner-Lambert Company Methods for inhibiting and controlling viral growth
US5489586A (en) 1994-03-07 1996-02-06 Warner-Lambert Company Method for treating inflammatory disease in humans
AU6944296A (en) 1995-09-13 1997-04-01 Takeda Chemical Industries Ltd. Benzoxazepine compounds, their production and use as lipid lowering agents
US5807876A (en) * 1996-04-23 1998-09-15 Vertex Pharmaceuticals Incorporated Inhibitors of IMPDH enzyme
RU6023U1 (ru) 1997-01-20 1998-02-16 АО "Автоэлектроника" Устройство управления для экономайзера принудительного холостого хода
US6025372A (en) 1997-04-04 2000-02-15 Merck & Co., Inc. Somatostatin agonists
US6057338A (en) 1997-04-04 2000-05-02 Merck & Co., Inc. Somatostatin agonists
AU1285499A (en) 1997-10-30 1999-05-24 Merck & Co., Inc. Somatostatin agonists
EP1177176B1 (en) 1999-04-28 2006-04-19 Aventis Pharma Deutschland GmbH Tri-aryl acid derivatives as ppar receptor ligands
RU11297U1 (ru) 1999-06-16 1999-09-16 Курзанов Евгений Владимирович Установка для выборочного измерения производительности нефтяных источников при групповом учете
AR035016A1 (es) 1999-08-25 2004-04-14 Takeda Chemical Industries Ltd Composicion de azol promotor de produccion/secrecion de neurotrofina, compuesto prodroga del mismo, composicion farmaceutica que lo comprende y uso del mismo para preparar esta ultima.
CA2383257C (en) 1999-08-26 2010-09-28 Christopher J. Burns Substituted (aminoiminomethyl or aminomethyl) dihydrobenzofurans and benozopyrans
EP1227090A4 (en) 1999-10-07 2002-11-20 Tadeka Chemical Ind Ltd AMINE DERIVATIVES
HK1045991B (en) 1999-11-10 2004-12-10 Takeda Pharmaceutical Company Limited 5-membered n-heterocyclic compounds with hypoglycemic and hypolipidemic activity
AU2223501A (en) * 1999-12-24 2001-07-09 Kyowa Hakko Kogyo Co. Ltd. Fused purine derivatives
EP1285651B1 (en) 2000-04-28 2010-09-01 Takeda Pharmaceutical Company Limited Melanin concentrating hormone antagonists
US7229986B2 (en) 2000-05-16 2007-06-12 Takeda Pharmaceutical Company Ltd. Melanin-concentrating hormone antagonist
US6429223B1 (en) * 2000-06-23 2002-08-06 Medinox, Inc. Modified forms of pharmacologically active agents and uses therefor
US7473691B2 (en) * 2000-09-15 2009-01-06 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6613776B2 (en) * 2000-09-15 2003-09-02 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
EP1317450B1 (en) * 2000-09-15 2006-11-22 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
US6660731B2 (en) * 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
RU2340611C2 (ru) 2000-09-15 2008-12-10 Вертекс Фармасьютикалз Инкорпорейтед Производные пиразола, используемые в качестве ингибиторов протеинкиназы
US6610677B2 (en) * 2000-09-15 2003-08-26 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
NZ526472A (en) * 2000-12-21 2004-04-30 Vertex Pharma Pyrazole compounds useful as protein kinase inhibitors
US20030096249A1 (en) * 2000-12-21 2003-05-22 Westphal Ryan S. Nucleic acid molecules and polypeptides for a human cation channel polypeptide
CA2442476A1 (en) * 2001-03-30 2002-10-10 Pfizer Products Inc. Pyridazinone aldose reductase inhibitors
TWI311133B (en) 2001-04-20 2009-06-21 Eisai R&D Man Co Ltd Carboxylic acid derivativeand the salt thereof
TW522326B (en) * 2001-08-03 2003-03-01 Inventec Corp Real-time data customer service system and method thereof
US6701066B2 (en) * 2001-10-11 2004-03-02 Micron Technology, Inc. Delivery of solid chemical precursors
WO2003042204A1 (en) 2001-10-19 2003-05-22 Takeda Chemical Industries, Ltd. Amine derivative
JP4166024B2 (ja) 2002-03-07 2008-10-15 独立行政法人科学技術振興機構 ２環式化合物およびその製造方法
EP1501815B1 (en) * 2002-04-26 2006-11-22 F. Hoffmann-La Roche Ag Substituted phenylacetamides and their use as glucokinase activators
AU2003252697A1 (en) * 2002-07-26 2004-02-16 Kyowa Hakko Kogyo Co., Ltd. Cell differentiation inductor
AU2003277576A1 (en) 2002-11-08 2004-06-07 Takeda Pharmaceutical Company Limited Receptor function controlling agent
US7572910B2 (en) * 2003-02-20 2009-08-11 Pfizer, Inc. Pyridazinone aldose reductase inhibitors
JPWO2004080943A1 (ja) 2003-03-11 2006-06-08 小野薬品工業株式会社 シンナミルアルコール誘導体化合物およびその化合物を有効成分として含有する薬剤
US7244763B2 (en) 2003-04-17 2007-07-17 Warner Lambert Company Llc Compounds that modulate PPAR activity and methods of preparation
EP1630152A4 (en) * 2003-05-30 2009-09-23 Takeda Pharmaceutical CONDENSED CYCLIC COMPOUND
JP4805552B2 (ja) * 2003-05-30 2011-11-02 武田薬品工業株式会社 縮合環化合物
TW200523252A (en) * 2003-10-31 2005-07-16 Takeda Pharmaceutical Pyridine compounds
RU2353617C2 (ru) 2003-10-31 2009-04-27 Такеда Фармасьютикал Компани Лимитед Производные пиридина в качестве ингибиторов дипептидилпептидазы iv
WO2005051890A1 (en) 2003-11-19 2005-06-09 Smithkline Beecham Corporation Aminophenylcyclopropyl carboxylic acids and derivatives as agonists to gpr40
AU2004309271A1 (en) * 2003-12-25 2005-07-14 Takeda Pharmaceutical Company Limited 3-(4-benzyloxyphenyl)propanoic acid derivatives
JP4074616B2 (ja) * 2003-12-25 2008-04-09 武田薬品工業株式会社 ３−（４−ベンジルオキシフェニル）プロパン酸誘導体
EP1698624B1 (en) * 2003-12-26 2012-06-27 Takeda Pharmaceutical Company Limited Phenylpropanoic acid derivatives
US7786165B2 (en) 2004-03-15 2010-08-31 Takeda Pharmaceutical Company Limited Aminophenylpropanoic acid derivative
JP4859665B2 (ja) * 2004-03-30 2012-01-25 武田薬品工業株式会社 アルコキシフェニルプロパン酸誘導体
UA90269C2 (ru) * 2004-04-02 2010-04-26 Мицубиси Танабе Фарма Корпорейшн Тетрагидрохинолиновые производные и способ их получения
TW200609219A (en) * 2004-06-17 2006-03-16 Neurogen Corp Aryl-substituted piperazine derivatives
JP3689711B1 (ja) 2004-12-24 2005-08-31 極東鋼弦コンクリート振興株式会社 真空グラウト注入方法
TW200637839A (en) * 2005-01-07 2006-11-01 Taisho Pharmaceutical Co Ltd 1-thio-d-glucitol derivatives
CA2598934A1 (en) * 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited Pyridyl acetic acid compounds
TW200815418A (en) 2006-06-27 2008-04-01 Astrazeneca Ab New compounds I
TW200811170A (en) 2006-06-27 2008-03-01 Sanofi Aventis Urea derivatives of tropane, their preparation and their therapeutic application
PE20080212A1 (es) 2006-06-27 2008-04-25 Sanofi Aventis Derivados de ureas de piperidina o pirrolidina como moduladores de la 11b-hidroxiesteroide deshidrogenasa tipo 1 (11bhsd1)

Also Published As

Publication number Publication date
RU2009102515A (ru) 2010-08-10
AU2007265966B2 (en) 2012-05-17
IL195947A0 (en) 2009-09-01
DK2248812T3 (da) 2014-03-10
PE20080993A1 (es) 2008-10-06
EP2041123B1 (en) 2012-02-01
TWI354668B (en) 2011-12-21
EP2431367A3 (en) 2012-07-04
GEP20115359B (en) 2011-12-26
DK2248812T5 (da) 2015-01-26
JP4917634B2 (ja) 2012-04-18
WO2008001931A2 (en) 2008-01-03
CY1112705T1 (el) 2016-02-10
EP2041123A2 (en) 2009-04-01
CO6160234A2 (es) 2010-05-20
EP2248812B1 (en) 2013-12-25
SI2248812T1 (sl) 2014-04-30
US20100197761A1 (en) 2010-08-05
CY1114978T1 (el) 2016-12-14
TW200811125A (en) 2008-03-01
NZ574038A (en) 2011-12-22
PL2248812T3 (pl) 2014-07-31
CN102731451B (zh) 2015-07-29
RS53230B (sr) 2014-08-29
CA2656003A1 (en) 2008-01-03
PL2041123T3 (pl) 2012-09-28
CN101616913B (zh) 2013-01-23
CN101616913A (zh) 2009-12-30
US20100004312A1 (en) 2010-01-07
US7732626B2 (en) 2010-06-08
IL195947A (en) 2013-07-31
US8088821B2 (en) 2012-01-03
KR101058772B1 (ko) 2011-08-24
CN103070854A (zh) 2013-05-01
UA95296C2 (uk) 2011-07-25
CA2838448A1 (en) 2008-01-03
MY154798A (en) 2015-07-31
BRPI0713378A2 (pt) 2012-04-03
CN102731451A (zh) 2012-10-17
ES2379661T3 (es) 2012-04-30
MA30537B1 (fr) 2009-06-01
US20130267589A1 (en) 2013-10-10
RU2444521C2 (ru) 2012-03-10
DK2041123T3 (da) 2012-05-07
JP4401428B2 (ja) 2010-01-20
HRP20140201T1 (hr) 2014-04-11
EP2248812A3 (en) 2011-03-16
KR20090027743A (ko) 2009-03-17
RS52307B (sr) 2012-12-31
JP2009280595A (ja) 2009-12-03
CA2656003C (en) 2014-03-25
AU2007265966A1 (en) 2008-01-03
JP5409757B2 (ja) 2014-02-05
EP2743268A2 (en) 2014-06-18
AR061644A1 (es) 2008-09-10
US8598226B2 (en) 2013-12-03
HRP20120333T1 (hr) 2012-05-31
US20120046338A1 (en) 2012-02-23
PT2248812E (pt) 2014-03-12
JP2012062320A (ja) 2012-03-29
US8492430B2 (en) 2013-07-23
EP2431367A2 (en) 2012-03-21
WO2008001931A3 (en) 2009-09-11
BRPI0713378A8 (pt) 2018-01-02
ES2450081T3 (es) 2014-03-21
CL2007001873A1 (es) 2008-01-04
PT2041123E (pt) 2012-04-09
ZA200900154B (en) 2010-03-31
SI2041123T1 (sl) 2012-05-31
JO2969B1 (en) 2016-03-15
ATE543815T1 (de) 2012-02-15
CN103083307A (zh) 2013-05-08
HK1131126A1 (en) 2010-01-15
EP2248812A2 (en) 2010-11-10
US20140080891A1 (en) 2014-03-20
CR10564A (es) 2012-06-18
ME00535B (me) 2011-10-10
MX2008016274A (es) 2009-01-15
EP2743268A3 (en) 2014-10-08
JP2009542580A (ja) 2009-12-03
EP2041123B9 (en) 2013-01-02

Similar Documents

Publication Publication Date Title
NO20090235L (no) Kondenserte sykliske forbindelser
NO20091948L (no) Indol forbindelse
EA200970746A1 (ru) Конденсированные циклические соединения в качестве частичных агонистов ppar-гамма
NO20081196L (no) Terapeutisk middel for diabetes
EA201071032A1 (ru) Гетероциклическое соединение
CR9830A (es) Compuestos de amino-5-[4-(difluorometoxi)fenil]-5-fenilimidazolona para la inhibicion de la b-secretasa
EA200900877A1 (ru) Пиперидиновые агонисты gpcr
NO20084307L (no) Heterocykliske GPCR agonister
NO20092711L (no) Metoder for anvendelse av cyclopaminanaloger
NO20084278L (no) Bezothiazol derivatives as beta2 adrenoreceptor agonists
EP1873144A4 (en) CONDENSED HETEROCYCLIC COMPOUND
NO20083026L (no) Terapeutisk middel for diabetes
NO20090295L (no) Substituerte heteroarylderivater
PH12013501099A1 (en) Bicyclic compound
NO20090173L (no) Kondensert spiroketalderivat og anvendelse derav som legemiddel for a behandle diabetes
NO20071222L (no) Benzamidforbindelser.
EA201071180A1 (ru) Конденсированные циклические соединения и их применение
GB0812642D0 (en) Compounds
UY33354A (es) Compuesto biciclico como inhibidor acc
DK1987025T3 (da) Benzoxazinon og benzoxazepinonoxazolidinoner som antibakterielle midler
NO20083065L (no) Nye N-sulfamoylpiperidinamider for profylakse eller behandling av overvekt og beslektede tilstander
NO20090234L (no) Tricyklisk sammensetning og farmasoytisk anvendelse derav
WO2009051223A1 (ja) 白内障処置のための医薬組成物
CL2014001377A1 (es) Compuestos derivados de n-(4-quinolilmetil)-sulfonamida, sus n-oxido o sus sales; composicion que los comprende, util para el tratamiento de infeccion por helmintos.
WO2007017892A3 (en) Novel compounds as glp-i agonists